 SHANGHAI and GAITHERSBURG, Md., April 26, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center, randomized, double-blind and placebo-controlled phase 2 study NCT03235752 evaluating the efficacy and safety of olamkicept also known as TJ301 administered intravenously biweekly in patients with active ulcerative colitis UC. 